人民财讯8月1日电，康鹏科技(688602)8月1日晚间公告，公司股东无锡云晖及其一致行动人星域惠天合 计持有公司5.94%股份。股东桐乡云汇及其一致行动人桐乡稼沃合计持有公司2.89%股份。因自身资金 安排，无锡云晖和星域惠天计划通过集中竞价、大宗交易方式减持公司股份合计不超过1558.13万股， 占康鹏科技总股份的3%。桐乡稼沃和桐乡云汇计划通过集中竞价、大宗交易方式减持康鹏科技股份合 计不超过1501.83万股，占康鹏科技总股份的2.89%。上述股东拟减持股份合计不超5.89%。 ...

康鹏科技公告，无锡云晖及一致行动人星域惠天计划2025年8月27日至2025年11月25日通过集中竞价减 持不超过519.38万股、大宗交易减持不超过1038.75万股，合计不超过1558.12万股，占公司总股本 3.00%；桐乡稼沃及一致行动人桐乡云汇同期通过集中竞价减持不超过519.38万股、大宗交易减持不超 过982.45万股，合计不超过1501.83万股，占公司总股本2.89%。 ...

Market Overview - A-shares experienced narrow fluctuations on July 25, with the Shanghai Composite Index down 0.10%, the Shenzhen Component down 0.20%, and the ChiNext Index down 0.21% [1] - The market showed active sectors including photolithography materials, with stocks like ASMC hitting the daily limit, and a rebound in the banking sector led by Ningbo Bank [1] - Declining sectors included Hainan concept stocks, diversified finance, and engineering materials, with coal mining, steel, liquor, and electric grid showing significant declines [1] Sector Highlights - The photolithography sector was notably active, with ASMC hitting the daily limit and other companies like Kangpeng Technology and Shanghai Xinyang also rising [2] - A significant development in extreme ultraviolet (EUV) photolithography materials was reported by Tsinghua University, which could provide new design strategies for advanced semiconductor manufacturing [2] Institutional Insights - Shenwan Hongyuan indicated that the necessary conditions for a bull market are gradually accumulating, with a favorable outlook for Q4 2025 as the market transitions towards 2026 expectations [3] - The focus on low-valuation cyclical stocks is recommended in the short term, while mid-term strategies should target midstream manufacturing sectors that may benefit from improving economic conditions and supply-side reforms [3] - Industrial rotation is expected to continue, with a focus on structural main lines as macroeconomic conditions remain stable, according to Industrial Securities [4] - Dongguan Securities noted that since the end of June, the total market value of A-shares has remained above 100 trillion yuan, reflecting market expansion and confidence in China's capital market [5]

Group 1 - The core viewpoint of the article highlights the significant growth in China's innovative drug development pipeline, which accounts for approximately 25% of the global total [1] - The Director of the Drug Registration Management Department of the National Medical Products Administration, Yang Ting, stated that around 3,000 clinical trial projects are conducted annually in China, placing the country among the leaders globally in this area [1] Group 2 - The stock prices of several companies in the pharmaceutical sector, including Boteng Co., Ltd., Kanglong Chemical, and Haitai Biological, saw notable increases, with Boteng Co., Ltd. rising nearly 10% and others rising over 5% [1] - The positive sentiment in the market is likely driven by the announcement regarding China's strong position in innovative drug development and clinical trials [1]

Core Viewpoint - Shanghai Kangpeng Technology Co., Ltd. has received approval from the UK Medicines and Healthcare products Regulatory Agency for a drug aimed at treating moderate to severe vasomotor symptoms (VMS) related to menopause, marking a significant advancement in women's health and demonstrating the company's strategic positioning in the pharmaceutical sector [1] Group 1: Technological Foundation - The approved drug is the world's first dual neurokinin (NK) targeted therapy, overcoming limitations of traditional hormone therapies and non-hormonal drugs [2] - The development of the core intermediate relies on Kangpeng's two decades of expertise in fluorination and carbon-carbon coupling technologies, enhancing drug targeting and metabolic stability [2] - As of the end of 2024, Kangpeng has accumulated 115 patents, including 66 invention patents, showcasing its robust technological foundation for pharmaceutical intermediate development [2] Group 2: Collaborative Model - The successful approval of the drug reflects Kangpeng's long-standing collaboration model with pharmaceutical companies, engaging in the early stages of drug development and expanding supply as the drug progresses to commercialization [3] - Kangpeng's client base includes renowned pharmaceutical companies such as Merck, Eli Lilly, and Bayer, indicating strong industry partnerships [3] - The drug's application for market approval is currently under review in major markets like the US and EU, with potential for significant revenue growth if approved [3] Group 3: Market Potential and Strategic Layout - VMS is a common symptom affecting 80% of women in the menopausal transition, highlighting a substantial market opportunity for new treatment options [5] - The global market for VMS treatments is projected to reach approximately $4.2 billion (around 30 billion RMB) in 2024, with an expected growth to $11.29 billion (around 80 billion RMB) by 2037, reflecting a compound annual growth rate of 7.9% [5] - Kangpeng's intermediate supply capabilities position the company to capitalize on this market growth, reinforcing its dual-track strategy and vision to become a leader in the fine chemicals sector in China [5][6] Group 4: Strategic Synergy - The company is expanding capacity in the new materials sector while simultaneously enhancing its pharmaceutical CDMO business through core technology transformation [6] - This synergy is expected to boost CDMO revenue in the short term and establish a more resilient long-term growth trajectory by engaging with multinational pharmaceutical companies and exploring new markets [6]

Core Viewpoint - On July 21, a total of 23 listed companies had their restricted shares unlocked, with a total market value of approximately 5.36 billion yuan [1] Summary by Category Restricted Share Unlocking - The specific details of the restricted share unlocking include: - Shandong High Energy (000803): 1.2772 million shares from equity incentive - Yueyang Xingchang (000819): 2.1525 million shares from equity incentive - Zhangyu A (000869): 2.0357 million shares from equity incentive - Sheneng Co., Ltd. (600642): 9.7161 million shares from equity incentive - Batian Co., Ltd. (002170): 1.2 million shares from equity incentive - Wanma Co., Ltd. (002276): 2.6112 million shares from equity incentive - Chuanfa Longmang (002312): 12.5 million shares from A-share issuance - Chengda Pharmaceutical (301201): 6.15594 million shares with extended lock-up period - Maoshuo Power (002660): 8.22983 million shares from A-share issuance - Laobaixing (603883): 193.6 thousand shares from equity incentive - Zhenbaodao (603567): 726.9 thousand shares from equity incentive - Lifang Pharmaceutical (003020): 234 thousand shares from equity incentive - Triangle Defense (300775): 110.4 thousand shares from equity incentive - Yidao Information (001314): 46.26 thousand shares from equity incentive - Honghe Technology (603256): 252.65 thousand shares from equity incentive - Guomao Co., Ltd. (603915): 165.8 thousand shares from equity incentive - Arrow Home (001322): 135.28 thousand shares from equity incentive - Hongying Intelligent (001266): 18 thousand shares from equity incentive - Kangpeng Technology (688602): 4.6189 million shares - Juyi Technology (688162): 108.1 thousand shares - Xidiwei (688173): 15.4 million shares - Aike Optoelectronics (688610): 68 thousand shares - Hangcai Co., Ltd. (688563): 180 thousand shares [1]

Core Viewpoint - The announcement details the upcoming release of restricted shares for Shanghai Kangpeng Technology Co., Ltd., with a total of 4,618,937 shares set to be listed for trading on July 21, 2025, after a 24-month lock-up period [1][2][3]. Group 1: Listing Details - The type of shares being listed is the first strategic placement shares, with a total of 4,618,937 shares, representing 0.89% of the company's total share capital [1][3]. - The total share capital of the company after the initial public offering (IPO) is 51,937,500 shares, with the restricted shares being part of the strategic placement [1][2]. - The listing date for the restricted shares is set for July 21, 2025, due to July 20, 2025, being a non-trading day [1][3]. Group 2: Shareholder Commitments - CITIC Jianzhong Investment Co., Ltd. is the sole shareholder of the restricted shares and has committed to a 24-month lock-up period from the date of the IPO [2]. - The shareholder has pledged not to use the acquired shares to influence the company's normal operations or seek control during the lock-up period [2]. - As of the announcement date, the shareholder has adhered to the commitments regarding the restricted shares, ensuring no breaches that would affect the listing [2]. Group 3: Verification by Intermediaries - The sponsor, CITIC Jianzhong Securities Co., Ltd., has confirmed that the shareholder has complied with the lock-up commitments [2]. - The listing of the restricted shares aligns with relevant regulations, including the Company Law and Securities Law of the People's Republic of China [2].

证券代码：688602 证券简称：康鹏科技 公告编号：2025-044 上海康鹏科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购方式 为网下，上市股数为4,618,937股。本公司确认，上市流通数量等于该限售期的全 部战略配售股份数量。 本次股票上市流通总数为4,618,937股。 本次股票上市流通日期为2025 年 7 月 21 日（因 2025 年 7 月 20 日为非交 易日，故上市流通日期顺延至下一交易日）。 截至本公告披露日，本次申请上市流通的限售股股东严格履行相应的承诺事 项，不存在相关承诺未履行影响本次限售股上市流通的情况。 一、 本次上市流通的限售股类型 2023 年 5 月 9 日，经中国证券监督管理委员会《关于同意上海康鹏科技股份 有限公司首次公开发行股票注册的批复》（证监许可〔2023〕1007 号）同意注册， 上海康鹏科技股份有限公司（以下简称"公司"）首次公开发行人 ...

中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐机构"） 作为上海康鹏科技股份有限公司（以下简称"公司"、"康鹏科技"）首次公开 发行股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业 务管理办法》《上海证券交易所科创板股票上市规则》等相关规定，对康鹏科技 首次公开发行部分限售股上市流通的事项进行了核查，具体情况如下： 一、 本次上市流通的限售股类型 2023 年 5 月 9 日，经中国证券监督管理委员会《关于同意上海康鹏科技股 份有限公司首次公开发行股票注册的批复》（证监许可〔2023〕1007 号）同意注 册，上海康鹏科技股份有限公司（以下简称"公司"）首次公开发行人民币普通 股（A 股）10,387.50 万股，并于 2023 年 7 月 20 日在上海证券交易所科创板挂 牌上市。公司首次公开发行后，总股本为 51,937.50 万股，其中有限售条件流通 股为 43,464.6325 万股，无限售条件流通股为 8,472.8675 万股。 本次上市流通的限售股为公司首次公开发行战略配售限售股，限售期为自公 司首次公开发行股票上市之日起 24 个月。本次涉及限售股东数量为 1 名 ...

Core Viewpoint - Kangpeng Technology is strategically expanding its presence in the pharmaceutical sector, particularly focusing on peptide business as a key development direction [1][2]. Group 1: Strategic Focus - In March 2025, Kangpeng Technology approved a project to enhance the manufacturing capacity of medical peptides, planning to invest 75 million yuan, marking a significant shift from traditional fine chemicals to innovative pharmaceutical raw materials [2]. - The company has a history of collaboration with pharmaceutical innovators, leveraging its technical advantages in the early stages of raw material drug development [2]. - Kangpeng Technology has accumulated 115 patents, including 66 invention patents, with core technologies centered around fluorination and carbon-carbon coupling, providing a solid foundation for peptide business development [2]. Group 2: R&D Breakthrough - In 2024, despite facing short-term pressure from intensified competition and weak market demand, Kangpeng Technology's R&D investment reached 85.39 million yuan, accounting for 12.65% of revenue, reflecting a commitment to a technology-driven strategy [3]. - The company is optimizing its new materials segment through dual strategies of process optimization and market expansion, with a complete industrial chain expected from the liquid crystal project in Quzhou [3]. - Kangpeng Technology has established stable partnerships with major pharmaceutical companies, including Merck, Eli Lilly, and Bayer, which positions it well for growth in the peptide raw material business [3]. Group 3: Compliance Operations - Kangpeng Technology emphasizes compliance and risk management, as evidenced by a recent legal dispute resolution that reduced the principal amount owed by 1.34 million yuan [5]. - The company has demonstrated transparency in information disclosure and has implemented a restricted stock incentive plan for 160 core personnel, signaling a commitment to long-term growth [6]. Group 4: Future Outlook - The company's focus on peptide business aligns with the growing demand for innovative drug raw materials, supported by government policies aimed at enhancing the drug pricing mechanism and promoting innovative drugs [7]. - With the advancement of the medical peptide manufacturing capacity enhancement project and the conversion of R&D investments into technological barriers, Kangpeng Technology is expected to achieve breakthroughs in the peptide sector, enriching its product pipeline in the pharmaceutical field [7].